CA3022354C - Procedes et compositions pour nanoparticules theranostiques
- Google Patents
Procedes et compositions pour nanoparticules theranostiques
Info
Publication number
CA3022354C
CA3022354CCA3022354ACA3022354ACA3022354CCA 3022354 CCA3022354 CCA 3022354CCA 3022354 ACA3022354 ACA 3022354ACA 3022354 ACA3022354 ACA 3022354ACA 3022354 CCA3022354 CCA 3022354C
Authority
CA
Canada
Prior art keywords
hbpe
nanoparticle
psma
nanoparticles
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Sanford Burnham Prebys Medical Discovery Institute
Memorial Sloan Kettering Cancer Center
University of Central Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute, Memorial Sloan Kettering Cancer Center, University of Central Florida Research Foundation IncfiledCriticalSanford Burnham Prebys Medical Discovery Institute
Priority claimed from PCT/US2016/029804external-prioritypatent/WO2016176462A1/fr
Publication of CA3022354A1publicationCriticalpatent/CA3022354A1/fr
Application grantedgrantedCritical
Publication of CA3022354CpublicationCriticalpatent/CA3022354C/fr
L'invention concerne des compositions et des procédés pour identifier une cible de cellule de tumeur solide. L'invention concerne par ailleurs des compositions et des procédés de traitement du cancer de la prostate. L'invention concerne en outre des compositions thérapeutiques contre le cancer comprenant le peptide CT20p. Des nanoparticules qui sont conjuguées avec un ligand de ciblage qui est un substrat pour une protéine de cellule spécifique d'une tumeur solide sont également décrites.
CA3022354A2015-04-282016-04-28Procedes et compositions pour nanoparticules theranostiques
ActiveCA3022354C
(fr)
Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c (-RGDfK-) 4